Evidence map›Paper›PMID 33895100›Full record

ArticleReumatologia clinica2021

Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia.

Natalia Mena-Vázquez, Sara Manrique Arija, Marta Rojas-Giménez, Enrique Raya-Álvarez, María Luisa Velloso-Feijoó, C López-Medina, Consuelo Ramos-Giraldez, Francisco Javier Godoy-Navarrete, Rocío Redondo-Rodríguez, Alba María Cabezas-Lucena and 3 more

Open access · greenAbstract read
In one paragraph

Article in Reumatologia clinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Natalia Mena-VázquezInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
Sara Manrique ArijaInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España. Electronic address: sarama_82@hotmail.com.
Marta Rojas-GiménezInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, España; Hospital Universitario Reina Sofía de Córdoba, Córdoba, España.
Enrique Raya-ÁlvarezHospital Universitario San Cecilio, Granada, España.
María Luisa Velloso-FeijoóHospital Virgen De Valme, Sevilla, España.
C López-MedinaInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, España; Hospital Universitario Reina Sofía de Córdoba, Córdoba, España.
Consuelo Ramos-GiraldezHospital Virgen De Valme, Sevilla, España.
Francisco Javier Godoy-NavarreteInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
Rocío Redondo-RodríguezInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
Alba María Cabezas-LucenaInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
M Morales-ÁguilaInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
C M Romero-BarcoInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Hospital Universitario Virgen de la Victoria de Málaga, Málaga, España.
Antonio Fernández-NebroInstituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España; Departamento de Medicina, Universidad de Málaga, Málaga, España.
Hospital Regional Universitario de Málaga · ESInstituto de Investigación Biomédica de Málaga · ESHospital Universitario de Valme · ESHospital Clínico Universitario Virgen de la Victoria · ESHospital Universitario Reina Sofía · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversidad de Málaga · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe whether rheumatic inflammatory diseases (RID) are associated with a higher risk of hospitalization and/or mortality from COVID-19 and identify the factors associated with hospitalization and mortality in RID and COVID-19 in different Hospitals in Andalusia.

methodsDesign: Multicentre observational case-control study. PATIENTS: RID and COVID-19 from different centres in Andalusia. CONTROLS: patients without RIS matched by sex, age and CRP-COVID. Protocol A list of patients with PCR for COVID-19 was requested from the microbiology service from March 14 to April 14, 2020. The patients who had RID were identified and then consecutively a paired control for each case. Variables The main outcome variable was hospital admission and mortality from COVID-19. Statistical analysis Bivariate followed by binary logistic regression models (DV: mortality/hospital admission).

resultsOne hundred and fifty-six patients were included, 78 with RID and COVID-19 and 78 without RID with COVID-19. The patients did not present characteristics of COVID-19 disease different from the general population, nor did they present higher hospital admission or mortality. The factor associated with mortality in patients with RID was advanced age (OR [95% CI], 1.1 [1.0-1.2]; p = 0.025), while the factors associated with hospitalization were advanced age (OR [95% CI], 1.1 [1.0-1.1]; p = 0.007) and hypertension (OR [95% CI], 3.9 [1.5-6.7]; p = 0.003).

conclusionMortality and hospital admission due to COVID-19 do not seem to increase in RID. Advanced age was associated with mortality in RID and, in addition, HTN was associated with hospital admission.

Indexed as

COVID-19Enfermedad inflamatoria reumáticaHospitalizaciónHospitalizationMortalidadMortalityRheumatic inflammatory disease

Identifiers

PMID33895100
PMCPMC7980141
OpenAlexW3200747293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.